lamivudine

Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Lamivudine 13C,15N2, an impurity of Lamivudine (BCH-189), functions as an inhibitor of both HIV-1/2 reverse transcriptase and hepatitis B virus reverse transcriptase, classifying it as a nucleoside reverse transcriptase inhibitor (NRTIs).

Lamivudine sulfoxide, (R)- is a metabolite of Lamivudine. Lamivudine is a potent nucleoside reverse transcriptase inhibitor and antiviral agent used for the treatment of chronic hepatitis B.

Lamivudine, (+ -)-trans- is a reverse transcriptase inhibitor and zalcitabine analog. It is used for the treatment of hepatitis B (HBV) and Human Immunodeficiency Virus Type 1 (HIV-1).

Lamivudine impurity A RS is a bioactive chemical.

Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase activity of both HIV-1 2 and hepatitis B virus, while also demonstrating the ability to penetrate the central nervous system [1] [2].

Lamivudine triphosphate (3TCTP), a phosphorylated form of the nucleoside analogue Lamivudine, inhibits the reverse transcriptase of HIV or HBV, blocking viral replication through chain termination. It also acts as an inhibitor of the RdRp activity of the HCVNS5B subunit. Additionally, Lamivudine triphosphate can be incorporated into nascent RNA by SARS-CoV-2 RdRp, thereby preventing mutations in the newly synthesized SARS-CoV-2 RNA.

Lamivudine-13C-d2 the 13C and deuterated compound of Lamivudine. Lamivudine has a CAS number of 134678-17-4. Lamivudine is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.

Apricitabine (SPD754) is a highly selective and orally active HIV-1 reverse transcriptase inhibitor (Ki=0.08 μM), the (-) enantiomer of 2′-deoxy-3′-oxy-4′-thiocytidine (dOTC) . Apricitabine inhibits DNA polymerase α, β and γ with Ki values of 300 μM, 12 μM and 112.25 μM, respectively. Apricitabine has shown good antiretroviral therapeutic efficacy in antiretroviral HIV-infected patients, with good tolerability and low selective resistance.

Tizoxanide (Desacetyl-nitazoxanide) is a metabolite of lamivudine. Lamivudine (2', 3'-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).

Bicyclol (SY801)(SY 801) is an anti-hepatitis drug. Oral administration of bicyclol normalizes the elevated serum transaminases (ALT, AST) by 50% in chronic viral hepatitis B and C, and also has a certain level of inhibiting HBV and HCV replication. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may reduce YMDD mutant and side effects and increase the anti-viral efficacy.

Besifovir Dipivoxil (LB80380) maleate is an oral prodrug of LB80317. Besifovir Dipivoxil maleate is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients.

Alamifovir is an antiviral drug specific for HBV. It is a purine nucleotide analog prodrug that is active against wild-type and lamivudine-resistant HBV and acts by inhibiting viral DNA initiation and viral DNA packaging, thereby reducing HBV replication.

TLR8 agonist 4 was effective in inhibiting both wild-type and drug-resistant (lamivudine and entecavir) HBV strains with their IC50 values of 0.15 and 0.10 μM, respectively.